Chronic treatment with novel small molecule Hsp90 inhibitors rescues striatal dopamine levels but not α-synuclein-induced neuronal cell loss

PLoS ONE

Volumn 9, Issue 1, 2014, Pages

  McFarland, Nikolaus R ^a   Dimant, Hemi ^b   Kibuuka, Laura ^b   Ebrahimi Fakhari, Darius ^c   Desjardins, Cody A ^b   Danzer, Karin M ^d   Danzer, Michael ^b   Fan, Zhanyun ^b   Schwarzschild, Michael A ^b   Hirst, Warren ^e   McLean, Pamela J ^f  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^d UNIVERSITY HOSPITAL ULM   (Germany)

^e PFIZER INC   (United States)

^f MAYO GRADUATE SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; DOPAMINE; HEAT SHOCK PROTEIN 90 INHIBITOR; SNX 0723; SNX 9114; UNCLASSIFIED DRUG; 2-FLUORO-6-(TETRAHYDROFURAN-3-YLAMINO)-4-(3,6,6-TRIMETHYL-4-OXO-4,5,6,7-TETRAHYDRO-1H-INDOL-1-YL)BENZAMIDE; ANTHRANILIC ACID DERIVATIVE; BENZAMIDE DERIVATIVE; HEAT SHOCK PROTEIN 90; INDOLE DERIVATIVE; PYRIMIDINE DERIVATIVE; SNX-9114;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE BRAIN LEVEL; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG TOLERABILITY; MALE; NERVE CELL DEGENERATION; NEUROMODULATION; NEUROTOXICITY; NONHUMAN; PARKINSONISM; RAT; SUBSTANTIA NIGRA; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; HUMAN; METABOLISM; NEOSTRIATUM; PARKINSON DISEASE; PATHOLOGY; SPRAGUE DAWLEY RAT;

ALPHA-SYNUCLEIN; ANIMALS; BENZAMIDES; DOPAMINE; HSP90 HEAT-SHOCK PROTEINS; HUMANS; INDOLES; MALE; NEOSTRIATUM; ORTHO-AMINOBENZOATES; PARKINSON DISEASE; PYRIMIDINES; RATS; RATS, SPRAGUE-DAWLEY; SUBSTANTIA NIGRA;

EID: 84908384520     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0086048     Document Type: Article

References (49)

1. McLean PJ, Kawamata H, Shariff S, Hewett J, Sharma N, et al. (2002) TorsinA and heat shock proteins act as molecular chaperones: suppression of alpha-synuclein aggregation. J Neurochem 83: 846-854. (Pubitemid 35316034)
2. Dimant H, Ebrahimi-Fakhari D, McLean PJ (2012) Molecular chaperones and co-chaperones in Parkinson disease. Neuroscientist 18: 589-601.
3. Petrucelli L, Dawson TM (2004) Mechanism of neurodegenerative disease: role of the ubiquitin proteasome system. Ann Med 36: 315-320. (Pubitemid 38789286)
4. Kon M, Cuervo AM (2010) Chaperone-mediated autophagy in health and disease. FEBS Lett 584: 1399-1404.
5. Ebrahimi-Fakhari D, Cantuti-Castelvetri I, Fan Z, Rockenstein E, Masliah E, et al. (2011) Distinct roles in vivo for the ubiquitin-proteasome system and the autophagy-lysosomal pathway in the degradation of alpha-synuclein. J Neurosci 31: 14508-14520.
6. Fujikake N, Nagai Y, Popiel HA, Okamoto Y, Yamaguchi M, et al. (2008) Heat shock transcription factor 1-activating compounds suppress polyglutamine-induced neurodegeneration through induction of multiple molecular chaperones. J Biol Chem 283: 26188-26197.
7. Bodner RA, Outeiro TF, Altmann S, Maxwell MM, Cho SH, et al. (2006) Pharmacological promotion of inclusion formation: a therapeutic approach for Huntington's and Parkinson's diseases. Proc Natl Acad Sci U S A 103: 4246-4251.
8. Deture M, Hicks C, Petrucelli L (2010) Targeting heat shock proteins in tauopathies. Curr Alzheimer Res 7: 677-684.
9. Klucken J, Shin Y, Masliah E, Hyman BT, McLean PJ (2004) Hsp70 Reduces alpha-Synuclein Aggregation and Toxicity. The Journal of biological chemistry 279: 25497.
10. Danzer KM, Ruf WP, Putcha P, Joyner D, Hashimoto T, et al. (2011) Heatshock protein 70 modulates toxic extracellular alpha-synuclein oligomers and rescues trans-synaptic toxicity. FASEB J 25: 326-336.
11. Auluck PK, Chan HY, Trojanowski JQ, Lee VM, Bonini NM (2002) Chaperone suppression of alpha-synuclein toxicity in a Drosophila model for Parkinson's disease. Science 295: 865-868. (Pubitemid 34118369)
12. McLean PJ, Klucken J, Shin Y, Hyman BT (2004) Geldanamycin induces Hsp70 and prevents alpha-synuclein aggregation and toxicity in vitro. Biochem Biophys Res Commun 321: 665-669. (Pubitemid 39127407)
13. Kalia SK, Kalia LV, McLean PJ (2010) Molecular chaperones as rational drug targets for Parkinson's disease therapeutics. CNS Neurol Disord Drug Targets 9: 741-753.
14. Chiosis G, Caldas Lopes E, Solit D (2006) Heat shock protein-90 inhibitors: a chronicle from geldanamycin to today's agents. Curr Opin Investig Drugs 7: 534-541. (Pubitemid 43891032)
15. Dickey CA, Eriksen J, Kamal A, Burrows F, Kasibhatla S, et al. (2005) Development of a high throughput drug screening assay for the detection of changes in tau levels - proof of concept with HSP90 inhibitors. Curr Alzheimer Res 2: 231-238. (Pubitemid 40862886)
16. Chiosis G, Tao H (2006) Purine-scaffold Hsp90 inhibitors. IDrugs 9: 778-782. (Pubitemid 44756117)
17. Waza M, Adachi H, Katsuno M, Minamiyama M, Sang C, et al. (2005) 17-AAG, an Hsp90 inhibitor, ameliorates polyglutamine-mediated motor neuron degeneration. Nat Med 11: 1088-1095. (Pubitemid 41486831)
18. Neckers L, Workman P (2012) Hsp90 molecular chaperone inhibitors: are we there yet? Clin Cancer Res 18: 64-76.
19. Gartner EM, Silverman P, Simon M, Flaherty L, Abrams J, et al. (2012) A phase II study of 17-allylamino-17-demethoxygeldanamycin in metastatic or locally advanced, unresectable breast cancer. Breast Cancer Res Treat 131: 933-937.
20. Chandarlapaty S, Sawai A, Ye Q, Scott A, Silinski M, et al. (2008) SNX2112, a synthetic heat shock protein 90 inhibitor, has potent antitumor activity against HER kinase-dependent cancers. Clin Cancer Res 14: 240-248. (Pubitemid 351378001)
21. Okawa Y, Hideshima T, Steed P, Vallet S, Hall S, et al. (2009) SNX-2112, a selective Hsp90 inhibitor, potently inhibits tumor cell growth, angiogenesis, and osteoclastogenesis in multiple myeloma and other hematologic tumors by abrogating signaling via Akt and ERK. Blood 113: 846-855.
22. Putcha P, Danzer KM, Kranich LR, Scott A, Silinski M, et al. (2010) Brain-permeable small-molecule inhibitors of Hsp90 prevent alpha-synuclein oligomer formation and rescue alpha-synuclein-induced toxicity. J Pharmacol Exp Ther 332: 849-857.
23. McFarland NR, Fan Z, Xu K, Schwarzschild MA, Feany MB, et al. (2009) Alpha-synuclein S129 phosphorylation mutants do not alter nigrostriatal toxicity in a rat model of Parkinson disease. J Neuropathol Exp Neurol 68: 515-524.
24. Ulusoy A, Decressac M, Kirik D, Bjorklund A (2010) Viral vector-mediated overexpression of alpha-synuclein as a progressive model of Parkinson's disease. Prog Brain Res 184: 89-111.
25. Koprich JB, Johnston TH, Reyes MG, Sun X, Brotchie JM (2010) Expression of human A53T alpha-synuclein in the rat substantia nigra using a novel AAV1/2 vector produces a rapidly evolving pathology with protein aggregation, dystrophic neurite architecture and nigrostriatal degeneration with potential to model the pathology of Parkinson's disease. Mol Neurodegener 5: 43.
26. St Martin JL, Klucken J, Outeiro TF, Nguyen P, Keller-McGandy C, et al. (2007) Dopaminergic neuron loss and up-regulation of chaperone protein mRNA induced by targeted over-expression of alpha-synuclein in mouse substantia nigra. Journal of neurochemistry 100: 1449-1457. (Pubitemid 46376202)
27. West MJ, Slomianka L, Gundersen HJ (1991) Unbiased stereological estimation of the total number of neurons in thesubdivisions of the rat hippocampus using the optical fractionator. The Anatomical Record 231: 482.
28. Chen X, Burdett TC, Desjardins CA, Logan R, Cipriani S, et al. (2013) Disrupted and transgenic urate oxidase alter urate and dopaminergic neurodegeneration. Proc Natl Acad Sci U S A 110: 300-305.
29. Waza M, Adachi H, Katsuno M, Minamiyama M, Tanaka F, et al. (2006) Modulation of Hsp90 function in neurodegenerative disorders: a molecular-targeted therapy against disease-causing protein. Journal of molecular medicine 84: 635-646. (Pubitemid 44162553)
30. Luo W, Sun W, Taldone T, Rodina A, Chiosis G (2010) Heat shock protein 90 in neurodegenerative diseases. Molecular neurodegeneration 5: 24.
31. Outeiro TF, Klucken J, Strathearn KE, Liu F, Nguyen P, et al. (2006) Small heat shock proteins protect against alpha-synuclein-induced toxicity and aggregation. Biochem Biophys Res Commun 351: 631-638. (Pubitemid 44780855)
32. Tetzlaff JE, Putcha P, Outeiro TF, Ivanov A, Berezovska O, et al. (2008) Chip targets toxic alpha -synuclein oligomers for degradation. J Biol Chem.
33. Shimshek DR, Mueller M, Wiessner C, Schweizer T, van der Putten PH (2010) The HSP70 molecular chaperone is not beneficial in a mouse model of alpha-synucleinopathy. PLoS One 5: e10014.
34. Hartl FU, Bracher A, Hayer-Hartl M (2011) Molecular chaperones in protein folding and proteostasis. Nature 475: 324-332.
35. Lo Bianco C, Shorter J, Regulier E, Lashuel H, Iwatsubo T, et al. (2008) Hsp104 antagonizes alpha-synuclein aggregation and reduces dopaminergic degeneration in a rat model of Parkinson disease. J Clin Invest 118: 3087-3097.
36. Daniele A, Moro E, Bentivoglio AR (1999) Zolpidem in progressive supranuclear palsy. N Engl J Med 341: 543-544.
37. Daturpalli S, Wang S, Buell A, Waudby C, Meehan S, et al. (2013) Hsp90 Inhibits alpha-Synuclein Aggregation by Interacting with Soluble Oligomers. J Mol Biol.
38. Zigmond MJ, Hastings TG, Abercrombie ED (1992) Neurochemical responses to 6-hydroxydopamine and L-dopa therapy: implications for Parkinson's disease. Ann N Y Acad Sci 648: 71-86.
39. Hornykiewicz O (1974) The mechanisms of action of L-dopa in Parkinson's disease. Life Sci 15: 1249-1259.
40. Finkelstein DI, Stanic D, Parish CL, Tomas D, Dickson K, et al. (2000) Axonal sprouting following lesions of the rat substantia nigra. Neuroscience 97: 99-112. (Pubitemid 30195880)
41. Lundblad M, Decressac M, Mattsson B, Bjorklund A (2012) Impaired neurotransmission caused by overexpression of alpha-synuclein in nigral dopamine neurons. Proc Natl Acad Sci U S A 109: 3213-3219.
42. Song DD, Haber SN (2000) Striatal responses to partial dopaminergic lesion: evidence for compensatory sprouting. J Neurosci 20: 5102-5114. (Pubitemid 30421713)
43. Shen HY, He JC, Wang Y, Huang QY, Chen JF (2005) Geldanamycin induces heat shock protein 70 and protects against MPTP-induced dopaminergic neurotoxicity in mice. J Biol Chem 280: 39962-39969. (Pubitemid 41779131)
44. Dong Z, Wolfer DP, Lipp HP, Bueler H (2005) Hsp70 gene transfer by adeno-associated virus inhibits MPTP-induced nigrostriatal degeneration in the mouse model of Parkinson disease. Mol Ther 11: 80-88. (Pubitemid 40012001)
45. London CA, Bear MD, McCleese J, Foley KP, Paalangara R, et al. (2011) Phase I evaluation of STA-1474, a prodrug of the novel HSP90 inhibitor ganetespib, in dogs with spontaneous cancer. PloS one 6: e27018.
46. Whitesell L, Shifrin SD, Schwab G, Neckers LM (1992) Benzoquinonoid ansamycins possess selective tumoricidal activity unrelated to src kinase inhibition. Cancer research 52: 1721-1728.
47. Neckers L, Lee YS (2003) Cancer: the rules of attraction. Nature 425: 357-359.
48. Kamal A, Thao L, Sensintaffar J, Zhang L, Boehm MF, et al. (2003) A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature 425: 407-410. (Pubitemid 37187270)
49. Flower TR, Chesnokova LS, Froelich CA, Dixon C, Witt SN (2005) Heat shock prevents alpha-synuclein-induced apoptosis in a yeast model of Parkinson's disease. J Mol Biol 351: 1081-1100. (Pubitemid 41133454)